Liothyronine is a fast-acting copy of the body's active thyroid hormone. Its clearest value is treating an underactive thyroid — especially for people still unwell on standard medication — and thyroid emergencies. A recent signal links it to less memory decline and death, but the evidence is mixed. In people without deficiency, boosting metabolism or lifespan is unsupported and risky. (Full Review)

Protocol

Standard Approach

Add-on to T4

~5–10 mcg liothyronine daily, replacing part of the T4 dose

Timing

Morning, empty stomach

30–60 min before food, separated from coffee and mineral supplements

Dosing Schedule

Split into two doses

Morning and early afternoon to smooth peaks and improve tolerability

Time to effect

Metabolic Effect

Hours to days

Metabolic and heart-rate effects begin

Acute Correction

2–4 hours

Intravenous onset in thyroid emergencies, versus 24–72 hours for oral T4

Well-being

6–12 weeks

Symptomatic improvement judged after reaching a stable dose

Benefits

High: Direct replacement of active thyroid hormone in hypothyroidism; rapid correction of severe hypothyroidism and myxedema coma

Medium: Reduced dementia and mortality risk with T3-containing therapy; symptom and quality-of-life improvement in T4 non-responders; augmentation of antidepressant response

Low: Cardiovascular support in low-T3 states; metabolic rate and weight effects

Speculative: Metabolic and longevity optimization in euthyroid adults; correction of age-related or low-T3-syndrome decline

Contraindications

Untreated adrenal insufficiency

Recent heart attack (within ~4–6 weeks unless specialist-supervised)

Uncontrolled overactive thyroid

Uncorrected cardiac arrhythmia

Pregnancy (T4 preferred)

Key Interactions

Oral anticoagulants (warfarin)

Cardiac glycosides (digoxin)

Antidiabetic drugs (insulin, sulfonylureas)

Tricyclic antidepressants, sympathomimetics

Decongestants (pseudoephedrine)

Antacids, calcium, iron, high-dose fiber

Biotin

Stimulant/thermogenic supplements (caffeine, synephrine, green tea)

Iodine-containing products (kelp)

Estrogen therapy

Risk & Side Effects

High: Cardiac overstimulation; supraphysiological hormone peaks from immediate-release dosing

Medium: Bone mineral density loss with chronic over-replacement; adrenergic-type symptoms

Low: Monitoring difficulty and iatrogenic thyrotoxicosis; muscle loss with misuse for weight reduction

Speculative: Long-term harm from unregulated or compounded products

Monitoring

Marker	Target	Why
Thyroid-stimulating hormone (TSH)	~0.5–2.5 mIU/L	Overall thyroid signal and marker of over-replacement
Free T4 (free thyroxine)	Mid-reference range	Storage-hormone level and conversion substrate
Free T3 (free triiodothyronine)	Upper-mid reference range	The active hormone being supplied; guides dosing
Total T3	Mid-to-upper reference range	Confirms adequate but not excessive replacement
Reverse T3 (rT3)	Low-normal	Flags inactive-hormone shunting in illness or stress
Resting heart rate	55–75 bpm	Early sign of over-stimulation
Bone mineral density (DXA)	T-score above −1.0	Detects long-term skeletal effect of excess hormone
Ferritin	~50–100 ng/mL	Iron status supports hormone conversion and energy

Cadence: 4–6 weeks after starting or changing dose, then every 3–6 months in the first year, and every 6–12 months thereafter

Qualitative Assessment

Sustained improvement in energy and reduced fatigue
Better cognitive clarity and mood
Normalized temperature tolerance and stable heart rate
Restful sleep without new insomnia or palpitations
Absence of tremor, anxiety, or heat intolerance signaling excess

Liothyronine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment